I-Mab

NovaBridge did not report revenue, EPS, gross margin, or year-over-year operating results on this corporate update call. The main reported hard numbers were the balance sheet figures: approximately $216 million in cash and investments at June 30, 2026, consisting of approximately $191 million in cash and cash equivalents and approximately $25 million in equity investment at fair value. Management said the current financial resources are expected to support the company through multiple clinical and strategic milestones, with runway extending through the anticipated Phase III interim data readout in 2028 for givastomig. For givastomig, management continued to target updated Phase Ib dose expansion data at ESMO, completion of enrollment in the Phase II first-line gastroesophageal adenocarcinoma combination study, and potential Phase III initiation as early as year-end 2026. For VIS-101, the company expects to initiate Phase IIb in the second half of 2026 and advance toward global Phase III development.

Srishti Gupta positioned NovaBridge as a company built to identify promising medicines and advance them through development, regulation, financing, and commercialization. Her tone was upbeat but grounded in execution, repeatedly emphasizing that structure should follow the asset and that the company is early in building out its broader platform. She highlighted two lead programs as examples of the model: givastomig as an oncology asset being pushed toward registrational development, and VIS-101 as an ophthalmology asset that was acquired and is being developed through a focused subsidiary.

Kyler Lei said NovaBridge ended June 30, 2026 with about $216 million in cash and investments, including about $191 million in cash and cash equivalents and about $25 million in equity investment at fair value. He stressed that the company has a debt-free balance sheet and said its current resources should fund multiple upcoming clinical and strategic inflection points. He specifically cited support for givastomig milestones through a potential Phase III interim readout in 2028, as well as continued development of VIS-101 and broader portfolio work. He also reiterated the company’s commitment to disciplined capital allocation and flexibility around financing, partnering, or corporate structure depending on each asset.

Analysts focused heavily on NovaBridge’s future growth strategy, especially how it plans to exploit European market gaps and why management believes it can source and develop differentiated assets there. Management said its edge comes from combining BD, clinical development, and commercial capabilities, and described Europe as an early but promising market where assets may be differentiated versus reimbursed standard of care and supported by efficient regulatory and manufacturing approaches. Questions also probed the screening funnel for more than 700 assets; management said the main filters are clinical development feasibility, regulatory path, likely payer/commercial uptake, and whether the team has conviction to advance or partner the asset. On givastomig, management clarified that FDA discussions were focused on the PD-L1-positive population and that PD-L1 <1% has not yet been discussed with the agency.